Market capitalization | $627.02m |
Enterprise Value | $380.25m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 2.65 |
Turnover (TTM) Turnover | $0.00 |
EBIT (operating result TTM) EBIT | $-109.70m |
Free cash flow (TTM) Free cash flow | $-86.99m |
Cash position | $248.98m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
9 Analysts have issued a Olema Pharmaceuticals Inc forecast:
9 Analysts have issued a Olema Pharmaceuticals Inc forecast:
Mar '24 |
+/-
%
|
||
Turnover | - - |
-
|
|
Gross income | -0.69 -0.69 |
59%
59%
|
|
EBITDA | -109 -109 |
2%
2%
|
EBIT (operating result) EBIT | -110 -110 |
3%
3%
|
Net profit | -99 -99 |
10%
10%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Olema Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of targeted therapies for women's cancers. The company also focuses on OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) that is being studied in a Phase 1/2 clinical trial for the treatment of metastatic or locally advanced ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema Pharmaceuticals was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.
Head office | United States |
CEO | Sean Bohen |
Employees | 74 |
Founded | 2006 |
Website | www.olema.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.